ClinicalTrials.gg

Program

lumrotatug

Also written as “CM313 injection”, “CM313” and “CM313(SC) injection”.

Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic, led by Keymed Biosciences.

Furthest: phase 3, since Oct 27, 202610 company-led studies, 8 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences108 open or runningphase 3since Oct 27, 2026Mar 24, 2021Mar 2027phase 2 · NCT06830395

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2021First study: phase 1 study in Multiple MyelomaFirst studyNCT04818372 · 87 enrolled · China
  2. Jul 7, 2022Phase 2 study in Lupus Erythematosus, SystemicNCT05465707 · 40 enrolled
  3. Nov 6, 2023Phase 2 study in Multiple MyelomaNCT06126237 · 120 planned
  4. Feb 22, 2024Phase 1 study in HealthyNCT06285227 · 51 planned · China
  5. Sep 10, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06594146 · 62 enrolled · China
  6. Jan 15, 20253 phase 2 studiesNCT06792019, NCT06791824, NCT06791772
  7. Feb 11, 2025Phase 2 study in Glomerulonephritis, IGANCT06830395 · 106 planned · China
  8. Oct 27, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07910903 · 320 planned · China

Ahead

  1. Mar 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT06830395
  2. Nov 16, 2027Primary completion: phase 2 study in Platelet Transfusion RefractorinessNCT06792019
  3. Dec 2027Primary completion: phase 2 study in Anemia, AplasticNCT06791824
  4. May 2030Primary completion: phase 3 study in Multiple MyelomaNCT07910903

TargetBeta

CD38 →read by rule
“A monoclonal antibody directed against the human cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), ”NCIt, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07910903Multiple Myeloma · China3Not yet recruitingMay 2030320
NCT06830395Glomerulonephritis, IGA · China2Not yet recruitingMar 2027106
NCT06791772Lupus Erythematosus, Systemic · China2Not yet recruitingOct 2026150
NCT06792019Platelet Transfusion Refractoriness · China2RecruitingNov 16, 2027110
NCT06791824Anemia, Aplastic · China2Not yet recruitingDec 2027125
NCT06594146Purpura, Thrombocytopenic, Idiopathic · China2Active, not recruitingDec 30, 202562
NCT06285227Healthy · China1RecruitingApr 30, 202551
NCT06126237Multiple Myeloma2Not yet recruitingFeb 28, 2026120
NCT05465707Lupus Erythematosus, Systemic2UNKNOWNOct 30, 202340
NCT04818372Multiple Myeloma · China1UNKNOWNJan 202387

How it is read

Names in the registry

  • “CM313 injection”, 5 entries
  • “CM313”, 3 entries
  • “CM313(SC) injection”, 3 entries
  • “CM313(SC) injection-low dose”, 1 entry
  • “CM313(SC) injection-high dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.